<DOC>
	<DOCNO>NCT01062061</DOCNO>
	<brief_summary>This survey conduct prepare application material re-examination Korean Pharmaceutical Affairs Laws Enforcement Regulation ; aim reconfirm clinical usefulness VARIVAX collect safety information accord Re-examination Regulation New Drugs .</brief_summary>
	<brief_title>Re-examination Study For Varivax ( V210-059 AM2 )</brief_title>
	<detailed_description>This post-marketing survey conduct usual routine practice investigator enrol participant vaccinate VARIVAX continuously study start . The purpose study assess occurrence adverse event identify factor may affect safety vaccine real-life , post-marketing condition . No hypothesis test conduct survey .</detailed_description>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Participants must vaccinate VARIVAX standard care Participants previously vaccinate VARIVAX Contraindication VARIVAX</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Varicella</keyword>
</DOC>